|
|
MEF2C |
myocyte enhancer factor 2C |
- ERK/MAPK targets
- Transcriptional activation of mitochondrial biogenesis
- Myogenesis
- MECP2 regulates transcription factors
- Heme signaling
- Cardiogenesis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
|
|
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
|
|
|
MEF2D |
myocyte enhancer factor 2D |
- Transcriptional activation of mitochondrial biogenesis
- Myogenesis
- NGF-stimulated transcription
- NGF-stimulated transcription
- Heme signaling
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
|
|
|
|
|
MGMT |
O-6-methylguanine-DNA methyltransferase |
- MGMT-mediated DNA damage reversal
|
- Cysteine
- Zinc
- S-Methylcysteine
- S-Benzylcysteine
- Dinitrochlorobenzene
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
MITF |
melanocyte inducing transcription factor |
- SUMOylation of transcription factors
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
|
- Malignant melanoma
- Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
- Waardenburg syndrome (WS)
|
|
|
MLXIPL |
MLX interacting protein like |
- PKA-mediated phosphorylation of key metabolic factors
- PKA-mediated phosphorylation of key metabolic factors
- AMPK inhibits chREBP transcriptional activation activity
- ChREBP activates metabolic gene expression
- ChREBP activates metabolic gene expression
- PP2A-mediated dephosphorylation of key metabolic factors
|
|
|
|
|
MN1 |
MN1 proto-oncogene, transcriptional regulator |
|
|
|
|
|
MORF4L1 |
mortality factor 4 like 1 |
|
|
|
|
|
MPG |
N-methylpurine DNA glycosylase |
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Displacement of DNA glycosylase by APEX1
|
- Cisplatin
- Zinc
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
MRE11 |
MRE11 double strand break repair nuclease |
- Cytosolic sensors of pathogen-associated DNA
- DNA Damage/Telomere Stress Induced Senescence
- IRF3-mediated induction of type I IFN
- HDR through Single Strand Annealing (SSA)
- HDR through MMEJ (alt-NHEJ)
- HDR through Homologous Recombination (HRR)
- Sensing of DNA Double Strand Breaks
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Meiotic recombination
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
- Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2)
- DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome
|
|
|
MSH6 |
mutS homolog 6 |
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Defective Mismatch Repair Associated With MSH2
- Defective Mismatch Repair Associated With MSH6
|
|
- Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
- Colorectal cancer
|
|
|
MSTO1 |
misato mitochondrial distribution and morphology regulator 1 |
|
|
|
|
|
MTOR |
mechanistic target of rapamycin kinase |
- PIP3 activates AKT signaling
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- HSF1-dependent transactivation
- Energy dependent regulation of mTOR by LKB1-AMPK
- CD28 dependent PI3K/Akt signaling
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
- Pimecrolimus
- Sirolimus
- Everolimus
- Rimiducid
- SF1126
- XL765
- Ridaforolimus
- Temsirolimus
- GSK-1059615
- Fostamatinib
- Oleandrin
|
|
|
|
MYB |
MYB proto-oncogene, transcription factor |
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
- Factors involved in megakaryocyte development and platelet production
- Specification of the neural plate border
|
|
|
|
|
MYBL2 |
MYB proto-oncogene like 2 |
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- Polo-like kinase mediated events
- TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
|
|
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- Signaling by ALK
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
- Regulation of CDH1 mRNA translation by microRNAs
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
- Acetylsalicylic acid
- Dimethyl sulfoxide
- Doconexent
- Nadroparin
|
- Penile cancer
- Breast cancer
- Laryngeal cancer
- Oral cancer
- Multiple myeloma
- Kaposi's sarcoma
- Ovarian cancer
- Choriocarcinoma
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Burkitt lymphoma
- Small cell lung cancer
- Osteosarcoma
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
|
|
MYOD1 |
myogenic differentiation 1 |
- Myogenesis
- Myogenesis
- TGFBR3 expression
|
|
|
|
|
N4BP2 |
NEDD4 binding protein 2 |
|
|
|
|
|
NAP1L1 |
nucleosome assembly protein 1 like 1 |
|
|
|
|
|
NAP1L4 |
nucleosome assembly protein 1 like 4 |
|
|
|
|
|
NBN |
nibrin |
- DNA Damage/Telomere Stress Induced Senescence
- HDR through Single Strand Annealing (SSA)
- HDR through MMEJ (alt-NHEJ)
- HDR through Homologous Recombination (HRR)
- Sensing of DNA Double Strand Breaks
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Meiotic recombination
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
- DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome
|